The Only Specialized Global Intellectual Property News Agency
A Member of Talal Abu-Ghazaleh Global

Moberg Pharma Announces Issue of European Patent for Kerasal Nail

28-May-2015 | Source : Moberg Pharma | Visits : 6308
STOCKHOLM - Moberg Pharma AB announced in a press release that the European Patent Office  has issued patent no. 2,777,689 for an improved formulation of Moberg Pharma’s market-leading OTC product for the treatment of fungal nails, sold in the US under the Kerasal Nail® brand. The patent expires in 2034.
The new European patent comprises composition of matter claims directed to novel formulations for topical application to the nails. The corresponding US patent was also granted earlier this spring and Moberg Pharma is pursuing patent approval in all major territories.
“The granted Kerasal Nail patents provide long-term intellectual property protection for our flagship product. It also reconfirms our commitment to bringing innovation to underserved niches and our long term goal to be the leading player in nail fungus,” said Peter Wolpert, CEO of Moberg Pharma AB.
Approximately 10% of the general population suffers from onychomycosis (nail fungus) and a majority of those afflicted go untreated. Kerasal Nail® is an OTC (over-the-counter) product based on a novel formulation of proven compounds and is clinically proven to rapidly improve the appearance of unsightly fungal nails. Kerasal Nail is applied to the damaged nail using a no-mess, silicone tip applicator. Its efficacy and safety have been documented in several clinical trials including more than 600 patients. Kerasal Nail has a unique rapid mechanism of action and has demonstrated compelling treatment results, including visible improvement within 2-4 weeks.
Moberg Pharma AB (publ) is a rapidly growing Swedish pharmaceutical company with OTC sales operations in the US and a distributor network in more than 40 countries. 

Related Articles